HOME >> BIOLOGY >> NEWS
OneWorld Health CEO outlines mutually beneficial collaborations between industry, nonprofits at BIO

San Francisco, Calif. June 7, 2004 The economics and traditional structure of drug development are shifting in ways that could lead to viable markets for new, affordable drugs in the developing world if biopharmaceutical companies considered innovative collaborations with nonprofits, according to Victoria Hale, Ph.D., founder and CEO of the Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S.

Dr. Hale will speak at the BIO 2004 Annual International Convention in San Francisco as part of the Global Health track in a panel session titled "Mutually Inclusive: New and Affordable Drugs for Developed, Developing Worlds." The session will take place today, June 7, at 2:15 pm in the Moscone Convention Center, Room #2007 West.

Dr. Hale will speak about her company's proven record of collaboration that enables drug companies to partner without compromising their profitability goals. "The benefits of such collaborations are vast," stated Dr. Hale. "By working with us and other like-minded nonprofits, industry is an active partner in bringing new, affordable drugs to cure infectious diseases in the developing world, and helps to nurture new markets."

New advances in biotechnology manufacturing, splitting of intellectual property between partners to cover various geographies and indications, donations of promising but unused intellectual property, and sharing investments and risks in drug development are some of the strategies OneWorld Health uses to create collaborations with industry.

The most vital resource needed to achieve successful collaborations is people -- professionals with biopharmaceutical expertise. Dr. Hale said OneWorld Health will seek out companies that offer executive loan or sabbatical programs that would allow their employees to lend their talents to the nonprofit pharmaceutical company in specific programs.

The panel consists of:
Chair: Tom Brewer, Senior Project Offic
'"/>

Contact: Joanne Hasegawa
jhasegawa@oneworldhealth.org
415-421-4700
Institute for OneWorld Health
7-Jun-2004


Page: 1 2

Related biology news :

1. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
2. Institute for OneWorld Health nominated for the 2004 World Technology Awards
3. Institute for OneWorld Health receives Gates Foundation grant
4. Institute for OneWorld Health CEO to speak at BIO on leveraging opportunities for global health
5. OneWorld Health completes enrollment, treatment in Phase III India trial
6. Institute for OneWorld Health CEO advocates focus first on developing world markets
7. OneWorld Health plans to form network of volunteer pharmaceutical scientists for global health
8. UC Santa Barbara donates discovery to OneWorld Health that may speed disease treatment
9. Victoria Hale of Institute for OneWorld Health Named Fellow by International Womens Forum
10. Health of worlds sea lions the focus of Wakefield Symposium
11. Healthy fats and oils essential to satisfy calorie-conscious consumers

Post Your Comments:
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... available in pharmacies and health stores, phosphatidylserine is ... and soy. Proven to improve cognition and slow ... people experiencing memory impairment. Now a team headed ... of Tel Aviv University,s Department of Human ... supplement improves the functioning of genes involved in ...
(Date:5/21/2013)... Try staying fit in space, where living quarters are ... That,s the challenge a group of Michigan State University ... grant from NASA. Their goal is to keep astronauts ... could give astronauts the best exercise regimen there is, ... it, it isn,t going to help," said project leader ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... Miami, FL (PRWEB) May 21, 2013 ... and breakouts as contributor to acne. Recently physicians from ... effects of mental stress on the skin, and suggested ... to help reduce the chemicals produced from stress that ... aside from the negative feelings acne brings about, stress ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome ... use its proprietary methodologies and expertise in genomic ... kinase targets in collaboration with Blueprint Medicines.  PGDx ... at identifying genomic alterations in tumors, and Blueprint ... kinase inhibitors for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
Cached News: